

# Hypothesis Testing

Wolfgang Huber, EMBL



Das Orakel zu Delphi.

fineart  
america


## Aims for this lecture

Understand the basic principles of hypothesis testing, and its pitfalls


What changes when we go from single to multiple testing?

Understand the benefits and pre-conditions of independent filtering

# Testing vs classification



## Accuracy vs Precision - Bias vs Variance



# Karl Popper (1902-1994)

Logical asymmetry between verification and falsifiability.

No number of positive outcomes at the level of experimental testing can confirm a scientific theory, but a single counterexample is logically decisive: it shows the theory is false.



# The four steps of hypothesis testing

**Step 1: Set up a model of reality: null hypothesis,  $H_0$**

**Step 2: Do an experiment, collect data**

**Step 3: Compute the probability of the data in this model**

**Step 4: Make a decision: reject the model if the computed probability is deemed too small**

$H_0$ : a model of reality that lets us make specific predictions of how the data should look like. The model is stated using the mathematical theory of probability.

**Examples of null hypotheses:**

- The coin is fair
- The new drug is no better or worse than a placebo
- The effect of that RNAi-treatment on my cells is no different than that of a negative control treatment



Points to make:

- The ordering of the 4 steps is an idealised scenario, followed e.g. in prospective clinical trials. It does not apply to retrospective 'data-mining'.

# The four steps of hypothesis testing

## Step 1: Set up a model of reality: null hypothesis, H<sub>0</sub>

Step

Step

Step

prob

H<sub>0</sub>: a

how

These are **not** null hypotheses:

- The number of heads and tails is the same
- The outcomes in my patient cohort are exactly the same
- The measured Cell-Titro signal from the cells is the same between RNAi-treatment and negative control

of

e

mathematical theory of probability.

Examples of null hypotheses:

- The coin is fair
- The new drug is no better or worse than a placebo
- The effect of that RNAi-treatment on my cells is no different than that of a negative control treatment



Points to make:

- The ordering of the 4 steps is an idealised scenario, followed e.g. in prospective clinical trials. It does not apply to retrospective 'data-mining'.

## Example


Toss a coin a number of times ⇒

If the coin is fair, then heads should appear half of the time (roughly).

But what is “roughly”? We use combinatorics / probability theory to quantify this.


For example, in 12 tosses with success rate p, the probability of seeing exactly 8 heads is

$$\binom{12}{8} p^8 \cdot (1 - p)^4$$



# Binomial Distribution

$H_0$  here:  $p = 0.5$ . Distribution of number of heads:



## Significance Level

If  $H_0$  is true and the coin is fair ( $p=0.5$ ), it is improbable to observe extreme events such as more than 9 heads

$$0.0193 = P(\text{heads} \geq 10 | H_0) = \text{"p-value"}$$

If we observe 10 heads in a trial, the null hypothesis is likely to be false.

An often used (but entirely arbitrary) cutoff is 0.05 ("significance level  $\alpha$ "): if  $p < \alpha$ , we reject  $H_0$

**Two views:**

Strength of evidence for a certain (negative) statement

Rational decision support

## Statistical Testing Workflow

1. Set up hypothesis  $H_0$  (that you want to reject)
2. Find a test statistic  $T$  that should be sensitive to (interesting) deviations from  $H_0$
3. Figure out the null distribution of  $T$ , if  $H_0$  holds
4. Compute the actual value of  $T$  for the data at hand
5. Compute p-value = the probability of seeing that value, or more extreme, in the null distribution.
6. Make a decision: reject  $H_0$  - yes / no ?

# Errors in hypothesis testing


Truth \ Decision	not rejected (‘negative’)	rejected (‘positive’)
Truth		
$H_0$ true	True negative (specificity)	False Positive Type I error $\alpha$
$H_0$ false	False Negative Type II error $\beta$	True Positive (sensitivity)

# One sample *t*-test

*t*-statistic (1908, William Sealy Gosset, pen-name “Student”)

$$t = \sqrt{n} \frac{\bar{x} - \mu_0}{\hat{\sigma}}$$

compare to a fixed value  $\mu_0$



Without  $n$ : *z*-score

With  $n$ : *t*-statistic

If data are normal, null distribution can be computed: “*t*-distribution”, with a parameter called “degrees of freedom”, equal to  $n-1$

statistic: any function of the data

## One sample *t*-test example

Consider the following 10 data points:

-0.01, 0.65, -0.17, 1.77, 0.76, -0.16, 0.88, 1.09, 0.96, 0.25

We are wondering if these values come from a distribution with a true mean of 0: one sample *t*-test


The 10 data points have a mean of 0.60 and a standard deviation of 0.62.

From that, we calculate the *t*-statistic:

$$t = 0.60 / 0.62 * 10^{1/2} \sim 3.0$$

## p-value and test decision

10 observations → compare observed  $t$ -statistic to the  $t$ -distribution with 9 degrees of freedom




p-value:  $P(|T_9| \geq 3.0) = 0.015$


In R: `pt(3.0, df=9, lower.tail=FALSE)`

# One-sided vs two-sided test

One-sided  
e.g.  $H_0: \mu < 0$



Two-sided  
e.g.  $H_0: \mu = 0$



## Two samples *t*-test

Do two different samples have the same mean ?

$$t = \frac{\bar{y} - \bar{x}}{SE}$$

$\bar{y}$  and  $\bar{x}$  are the average of the observations in the two populations

SE is the standard error for the difference

If  $H_0$  is correct, test statistic follows a *t*-distribution with  $n+m-2$  degrees of freedom  
( $n, m$ : number of observations in each sample)

## t-test in R

```
t.test(x, y = NULL,  
       alternative = c("two.sided", "less", "greater"),  
       mu = 0, paired = FALSE, var.equal = FALSE,  
       conf.level = 0.95, ...)
```

**x, y:** Data (only x needs to be specified for one-group test, specify target **mu** instead)

**paired:** paired (e.g. repeated measurements on the same subjects) or unpaired

**var.equal:** Can the variances in the two groups assumed to be equal?

**alternative:** one- or two-sided test?

## Avoid fallacy

The p-value is the probability that the data could happen, under the condition that the null hypothesis is true.

It is not the probability that the null hypothesis is true.

Absence of evidence ≠  
evidence of absence



## Comments and pitfalls







The derivation of the  $t$ -distribution assumes that the observations are independent and that they follow a Normal distribution.

**Deviation from Normality** - heavier tails: test still maintains type-I error control, but may no longer have optimal power.


Options: Wilcoxon test, permutation tests

If the data are **dependent**, then p-values will likely be totally wrong (e.g., for positive correlation, too optimistic).

## different data distributions – independent case



## t-test can loose error control if independence assumption does not hold



```

library("mvtnorm")
library("genefilter")

p = 30      ## number of samples
n = 20000   ## number of genes

mu = rep(0, p)
dp = diag(p)

sigma = list(
  'uncorrelated' = dp,          ## unity matrix
  'correlated (band-diagonal)' = ## band diagonal
    (row(dp)==col(dp)) + 0.5 * (abs(row(dp)-col(dp))==1))

lapply(sigma, print)

## generate data
x = lapply(sigma, function(s) rmvnorm(n = n, mean = mu, sigma = s))

## tests
tt = lapply(x, rowttests)

par(mfrow=c(length(tt), 1))
for(i in seq(along=tt))
  hist(tt[[i]]$p.value, breaks=100, col=c("skyblue", "orange")[i], main=names(tt)[i], xlab="p value")

```

## **Summary single hypothesis testing**

We ‘prove’ something by rejecting the opposite (the null hypothesis)

Not rejecting does not prove the null hypothesis

All this reasoning is probabilistic

p-values are intended to be used for rational decision making

In genomics, they’re often also used for data integration

## Editorial

David Trafimow and Michael Marks  
New Mexico State University

The *Basic and Applied Social Psychology* (BASP) 2014 Editorial emphasized that the null hypothesis significance testing procedure (NHSTP) is invalid, and thus authors would not be required to perform it (Trafimow, 2014). However, to allow authors a grace period, the Editorial stopped short of actually banning the NHSTP. The purpose of the present Editorial is to announce that the grace period is over. From now on, BASP is banning the NHSTP.

With the banning of the NHSTP from BASP, what are the implications for authors? The following are anticipated questions and their corresponding answers.

**Question 1.** Will manuscripts with *p*-values be desk rejected automatically?

**Answer to Question 1.** No. If manuscripts pass the preliminary inspection, they will be sent out for review. But prior to publication, authors will have to remove all vestiges of the NHSTP (*p*-values, *r*-values, *F*-values, statements about "significant" differences or lack thereof, and so on).

**Question 2.** What about other types of inferential statistics such as confidence intervals or Bayesian methods?

**Answer to Question 2.** Confidence intervals suffer from an inverse inference problem that is not very different from that suffered by the NHSTP. In the NHSTP, the problem is in traversing the distance from the probability of the finding, given the null hypothesis, to the probability of the null hypothesis, given the finding. Regarding confidence intervals, the problem is that, for example, a 95% confidence interval does not indicate that the parameter of interest has a 95% probability of being within the interval. Rather, it means merely that if an infinite number of samples were taken and confidence intervals computed, 95% of the confidence intervals would capture the population parameter. Analogous to how the NHSTP fails to provide the probability of the null hypothesis, which is needed to provide

Correspondence should be sent to David Trafimow, Department of Psychology, MSC 3452, New Mexico State University, P.O. Box 30001, Las Cruces, NM 88003-8001. E-mail: dtrafimo@nmsu.edu

a strong case for rejecting it, confidence intervals do not provide a strong case for concluding that the population parameter of interest is likely to be within the stated interval. Therefore, confidence intervals also are banned from BASP.

Bayesian procedures are more interesting. The usual problem with Bayesian procedures is that they depend on some sort of Laplacian assumption to generate numbers where none exist. The Laplacian assumption is that when in a state of ignorance, the researcher should assign an equal probability to each possibility. The problems are well documented (Chiara, 1994; Fisher, 1973; Glymour, 1980; Popper, 1983; Suppes, 1994; Trafimow, 2003, 2005, 2006). However, there have been Bayesian proposals that at least somewhat circumvent the Laplacian assumption, and there might even be cases where there are strong grounds for assuming that the numbers really are there (see Fisher, 1973, for an example). Consequently, with respect to Bayesian procedures, we reserve the right to make case-by-case judgments, and thus Bayesian procedures are neither required nor banned from BASP.

**Question 3.** Are any inferential statistical procedures required?

**Answer to Question 3.** No, because the state of the art remains uncertain. However, BASP will require strong descriptive statistics, including effect sizes. We also encourage the presentation of frequency or distributional data when that is feasible. Finally, we encourage the use of large sample sizes that is typical in much psychological research, because as the sample size increases, descriptive statistics become increasingly stable and sampling error is less of a problem. However, we will stop short of requiring particular sample sizes, because it is possible to imagine circumstances where more typical sample sizes might be justifiable.

We conclude with one last thought. Some might view the NHSTP ban as indicating that it will be easier to publish in BASP, or that less rigorous manuscripts will be acceptable. This is not so. On the contrary, we believe



## Psychology journal bans *P* values

Test for reliability of results 'too easy to pass', say editors.

Chris Woolston

26 February 2015 | Clarified: 09 March 2015

PDF Rights & Permissions

A controversial statistical test has finally met its end, at least in one journal. Earlier this month, the editors of *Basic and Applied Social Psychology* (BASP) announced that the journal would no longer publish papers containing *P* values because the statistics were too often used to support lower-quality research<sup>1</sup>.

Authors are still free to submit papers to BASP with *P* values and other statistical measures that form part of 'null hypothesis significance testing' (NHST), but the numbers will be removed before publication. Nerisa Dozo, a PhD student in psychology at the University of Queensland in Brisbane, Australia, tweeted:

## Good discussion thread:

<http://stats.stackexchange.com/questions/139290/a-psychology-journal-banned-p-values-and-confidence-intervals-is-it-indeed-wise>


"A bad workman blames his tools."

## Problems:


retrospective data picking  
posthoc changes to the null hypothesis  
use of the 5% threshold

## Possible solutions:

Bayesianism, skeptical priors  
Report the data and all analytical choices (reproducible document)



xkcd



xkcd

## Multiple Testing Examples

Many data analysis approaches in genomics rely on item-by-item (i.e. multiple) testing:

- RNA-Seq (or  $\mu$ array) expression profiles of “normal” vs “perturbed” samples: gene-by-gene
- ChIP-Seq: locus-by-locus
- RNAi and chemical compound screens
- Genome-wide association studies (GWAS): marker-by-marker
- QTL analysis: marker-by-marker and trait-by-trait


## The Multiple Testing Problem

When performing many tests, the type I error goes up:  
for  $\alpha = 0.05$  and  $n$  tests, the probability of no false positive result is:

$$\underbrace{0.95 \cdot 0.95 \cdot \dots \cdot 0.95}_{n\text{-times}} \lll 0.95$$

The larger the number of tests performed, the higher the probability of a false rejection ( $\rightarrow 1$ )

# The Multiple Testing Opportunity



The Bayesian can be so confident since equivalent tests have been performed for billions of years before. So he can put a very low prior on this particular test today (—> DESeq2 lectures)

## False positive rate and false discovery rate

FPR: fraction of FP among all genes (etc.) tested

FDR: fraction of FP among hits called

**Example:**  
20,000 genes, 100 hits, 10 of them wrong.

FPR: 0.05%

FDR: 10%



## Experiment-wide type I error rates

	Not rejected	Rejected	Total
True null hypotheses	U	V	$m_0$
False null hypotheses	T	S	$m_1$
Total	$m - R$	R	m

**Family-wise error rate (FWER):** The probability of one or more false positives,  $P(V > 0)$ . For large  $m_0$ , this is difficult to keep small.


**False discovery rate (FDR):** The expected fraction of false positives among all discoveries,  $E[V / \max\{R, 1\}]$ .

## Bonferroni correction



For  $m$  tests, multiply each  $p$ -value with  $m$ .  
Then see if anyone still remains below  $\alpha$ .


## False discovery rate




Observed p-values are a mix of samples from

- a uniform distribution ( $\leftarrow$  nulls) and
- from one (more) distributions concentrated at 0 ( $\leftarrow$  alternatives)


## Benjamini Hochberg method



## Benjamini Hochberg method



## How to estimate the number (not: the identity) of differentially expressed genes



For a series of hypothesis tests  $H_1, \dots, H_m$  with  $p$ -values  $p_i$ , plot

$$(1 - p_i, N(p_i)) \quad \text{for all } i$$


where  $N(p)$  is the number of  $p$ -values greater than  $p$ .

Red line:  $(1 - p_i, (1 - p)m)$


$(1 - p)m$  = expected number of  $p$ -values greater than  $p$

Schweder T, Spjøtvoll E (1982) Plots of P-values to evaluate many tests simultaneously.  
*Biometrika* 69:493–502. See ‘genefilter’ vignette for an example.


# parathyroid dataset




# parathyroid dataset



Histogram of res\$pvalue



# parathyroid dataset



## Independent filtering

From the set of all tests to be done,  
first filter out those that seem to have insufficient power  
anyway,  
then formally test for differential expression on the rest.


### Literature

von Heydebreck, Huber, Gentleman (2004)  
Chiaretti et al., Clinical Cancer Research (2005)  
McClintick and Edenberg (BMC Bioinf. 2006) and references therein  
Hackstadt and Hess (BMC Bioinf. 2009)  
Bourgon, Gentleman and Huber (PNAS 2010)  
Many others.

## Independent filtering can increase detection rates

Stage 1 filter: sum of counts, across samples, for each gene, and remove the fraction (10%, 20%, ...) of genes where that is smallest

Stage 2: standard NB-GLM test



## Really?

Increased detection rate implies increased power  
only if we are still controlling type I errors at the same level  
as before.



# Really?

Increased  
only if  
as before

## Concern:


Since we use a data-driven criterion in stage 1, but do p-value and type-I error related computations only on the genes in stage 2, aren't we 'cheating'?

## Informal justification:

Filter does not use covariate information




# What makes a good filter?



genefilter vignette

## How to choose the filter cutoff?




genefilter vignette

DESeq2 - inbuilt default

Caveat - overfitting, optimism of there are no alternatives

## Acknowledgments



Robert Gentleman



Richard Bourgon



Nikos  
Ignatiadis

STUCK IN A DULL, LOW PAYING JOB?  
WANT TO MAKE BIG MONEY?

BE A  
QUANTUM  
MECHANIC!

...EVEN IF YOU NEVER  
FINISHED HIGH SCHOOL!

STUDY AT HOME

THE COLUMBIA INSTITUTE OF QUANTUM MECHANICS, INC.

Not affiliated with the Columbia Broadcasting System, Columbia University, the District of Columbia, or Columbia, Gem of the Ocean.



BY MAIL AND SEND

Yes! I want to get in on the ground floor of this exciting new field. I understand no salesman will call.

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

CITY, STATE, ZIP \_\_\_\_\_

COLUMBIA INSTITUTE OF QUANTUM MECHANICS  
Suite 293, 1100 Back St., Providence, RI 02904